Close

Nasal Covid-19 Vaccine From Bharat Biotech, A Possibility

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

China Unveils Innovative Drugs Policy to Boost Development

The National Health Commission and China's National Healthcare Security...

Ensuring optimal product integrity with pharmaceutical preservation strategies

Preserving the potency of pharmaceutical products is paramount in...

How Stem Cell Therapy Works for the Individual

Stem cell therapy has emerged as one of the...

Tjoapack Expands Injectable Packaging Capabilities Globally

Increased Capabilities in the United States Tjoapack is finishing up...

Bharat Biotech has been granted permission by India’s drug controller to execute standalone phase 3 clinical trials on the intranasal vaccine for COVID-19. Besides this, the drug regulator has also authorised the Indian biotech giant, which is based in Hyderabad, to analyse BBV 154, the intranasal vaccine as a booster which can be used on people who have already been inoculated with both doses of Covaxin.

Notably, Bharat Biotech has come up with this single-dose intranasal vaccine in collaboration with Washington University, based in St. Louis, US. The fact is that, if found effective, it will undoubtedly bring a revolution in the fight against the pandemic across the world. As per the company’s statement, intranasal vaccines are pretty easy to administer when it comes to carrying out mass inoculations, and this will further help in reducing or even stopping the spread to a significant extent. Plans are to conduct trials on 5000 people across nine locations in India. If the approval comes, the intranasal vaccine could be given six months post-second jab.

Earlier in January 2022, the SEC-Subject Expert Committee, which comes under the drug regulator, had asked for Bharat Biotech’s application in this regard. This development is being seen as a boon for a vast country like India, a. because it will be a single dose and b. because it will be easy to administer, which means less time consumption per person.Bharat Biotech’s Chairman, Krishna Ella, said in a statement earlier that intranasal at any point would prove to be a great choice as it can be given to two-month-old babies as well as the entire population, barring pregnant women and people suffering from cancer. It is well to be noted that India has already started administering the booster dose this month for its senior citizens and frontline workers.

Latest stories

Related stories

China Unveils Innovative Drugs Policy to Boost Development

The National Health Commission and China's National Healthcare Security...

Ensuring optimal product integrity with pharmaceutical preservation strategies

Preserving the potency of pharmaceutical products is paramount in...

How Stem Cell Therapy Works for the Individual

Stem cell therapy has emerged as one of the...

Tjoapack Expands Injectable Packaging Capabilities Globally

Increased Capabilities in the United States Tjoapack is finishing up...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back